Journey Medical (DERM) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical (DERM) has outperformed SIGA Technologies (SIGA) over the past year, losing 21.2% versus a loss of 61.4%. SIGA Technologies is the larger company by market cap ($234.2 million vs $167.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | SIGA |
|---|---|---|
| Share price | $5.95 | $3.26 |
| Market cap | $167.94M | $234.23M |
| 1-day change | -3.41% | -0.91% |
| YTD return | -22.83% | -46.64% |
| 1-year return | -21.19% | -61.37% |
| 5-year return | — | -54.15% |
| Forward P/E | — | 3.02 |
| EPS (TTM) | $-0.22 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $8.55 |
| 52-week low | $4.31 | $2.83 |
| Distance from 52-week high | -37.73% | -61.87% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +131.09% | — |
| Average volume | 182.16K | 726.50K |
| Shares outstanding | 22.22M | 71.85M |
| Employees | 58 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed SIGA by 40.2 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
DERM vs SIGA FAQ
Which is bigger, Journey Medical or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $234.23M compared with $167.94M for Journey Medical (DERM).
Which stock has performed better over the past year, DERM or SIGA?
DERM returned -21.19% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.